ERAS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - August 10, 2026 Deadline

Erasca, Inc. faces a securities class action lawsuit alleging that the company and its executives made false statements about its lead drug candidate ERAS-0015. The lawsuit claims Erasca's preclinical data involved improper comparisons and failed to disclose patent infringement risks from Revolution Medicines. Following disclosure of a patent assertion letter and adverse clinical trial data on April 27, 2026, Erasca's stock fell approximately 59% over two trading days. Investors with substantial losses can seek lead plaintiff status by August 10, 2026.